Simulations Plus
Simulations Plus provides modeling and simulation software for drug discovery and clinical development, along with consulting services in various pharmacological fields. The company offers a range of software products, hosts educational events, and has been listed on NASDAQ under the symbol SLP since 1999.
Services
Simulations Plus provides a comprehensive suite of modeling and simulation software for drug discovery, clinical development research, and regulatory submissions. Their consulting services span early drug discovery, physiologically based pharmacokinetics (PBPK), quantitative systems pharmacology (QSP), clinical pharmacology & pharmacometrics (CPP), and regulatory strategies. Additionally, the company offers consulting packages such as Consult + Coach, First-in-Human Simulator, and Pulmonary Package. Other services include a Concierge program and Learning Services aimed at enhancing client capabilities.
Products
Simulations Plus has developed an array of software products designed for various aspects of drug development. Notable offerings include GastroPlus®, MonolixSuite™, ADMET Predictor®, DILIsym®, DDDPlus™, NAFLDsym®, MembranePlus™, OBESITYsym™, PKanalix®, Simulx®, IPFsym®, ILDsym®, RENAsym®, and MedChem Designer™. These products aid in PBPK modeling, ADMET property prediction, drug-drug interaction assessment, and quantitative systems pharmacology/toxicology.
Scientific Events and Learning Services
Simulations Plus actively hosts a range of scientific events designed to keep clients and industry professionals informed and educated. Their events include webinars, live workshops, on-demand workshops, and scientific meetings. The company also boasts a Resource Center filled with blogs, journal articles, flyers, posters, presentations, press releases, videos, white papers, and webinars. Educational initiatives include the University+ program, which offers one-year access to software for students and educators at accredited universities globally.
Corporate Development and Acquisitions
In its pursuit of growth and innovation, Simulations Plus has initiated several corporate development strategies and an Environmental, Social, and Governance (ESG) program. Notably, the company acquired Immunetrics, which has strengthened their capabilities in immunology and oncology drug development. This acquisition is part of their broader effort to expand their service and product offerings.
History and Market Presence
Simulations Plus has celebrated over 25 years in business and maintains a substantial market presence with more than 280 clients, including 19 out of the top 20 pharmaceutical companies globally. The company's reputation is built on its robust software solutions for modeling and simulation in drug development, including validated machine learning, QSP, QST, HTPK, PBPK, and PBBM software. Since 1999, Simulations Plus has been listed on the NASDAQ under the symbol SLP, reflecting its established presence in the industry.